This year the whole team of Kymos has a Christmas surprise for our clients and partners: An Online Christmas Calendar (Click here) Click on the link and find the Christmas greetings from our individual departments. Open a door every day, see funny and contemplative moments and find a surprise or two. We all had a (...) Read more
In June 2022 the FDA published a draft version of a new guideline about “Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics”. The guideline provides recommendations to assist the industry in the development of oligonucleotide therapeutics. This poses new challenges for oligonucleotide therapeutics developers and manufacturers. Maria Fauth, Department Manager Oligonucleotides at Kymos, explains (...) Read more
Climate change, gas and electricity crisis, high inflation. These are challenges all of us are facing every day. Kymos is now taking action: We have invested in sustainability and in our future with new SolarPannels on Kymos buildings. The new photovoltaic installation is composed of 264 solar panels of 490Wp, which means 129.36 kWp of (...) Read more
Elemental impurities in pharmaceutical but also cosmetic products are increasingly receiving the attention of the authorities. New limits are being defined constantly and it is essential to always be up to date with the latest regulations. Gemma Solsona, Head of Department for Elemental Impurities, informs about the most important recent regulatory developments: “Currently, several changes (...) Read more
Bioequivalence studies are designed to show that two drugs are equivalent and substitutable. - But even though the medicines are replaceable, the providers of bioequivalence studies are not. Digna Tost, Department Manager of Bioanalysis of Small Molecules at Kymos, resumes why Kymos is the right partner for bioequivalence projects: "Our clients are looking for (...) Read more
In 2023, Pharmaprogress will move into a more spacious, convenient, and state-of-the-art building in the Ancona area. Luca Gramaccioni, General Site Manager of Pharmaprogress, and his team are excited about having more room soon: "In 2001, Pharmaprogress was established in the current building. After 20 years the team increased from the original 6 to 26 (...) Read more
In recent months, we unfortunately had to turn down repeated requests for dissolution tests for which we would have needed the Dissolution USP 4 CE 7smart device. This was neither satisfactory for our customers nor for us. We have taken this situation seriously and ated accordingly: A brand-new Dissolution USP 4 CE 7smart device will (...) Read more
For almost 20 years, Kymos’ German subsidiary Prolytic has accompanied Aeterna Zentaris in its development of pharmaceutical and diagnostic products. Katrin Dorfmeyer, Head of Chromatography, at Prolytic, and Dr. Michael Teifel, CSO at Aeterna Zentaris, shed light on the interesting project of the growth hormone secretagogue macimorelin (Macrilen, Ghryvelin) which they have been working on (...) Read more
Lisa Hentschel, Master of Molecular Biosciences, started her career at Prolytic eight years ago as a technician in the ELISA team. Since 2017, she now leads the Biology Department and is a recognized expert in large molecule bioanalysis, ADA determination and enzyme activity measurement. Together with Dr Busch, COO at Eleva, she shares her (...) Read more
The bioanalysis of nucleic acids, especially in biological matrices, is one of the newest services offered by the Kymos Group and carried out at its German subsidiary Prolytic. Maria Fauth, Head of the Oligonucleotides Department, has dedicated her entire academic and corporate career to the research and analysis of nucleic acids. She and Dr. Janine (...) Read more
